179 related articles for article (PubMed ID: 24336076)
21. Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells.
Siegel D; Shieh B; Yan C; Kepa JK; Ross D
J Pharmacol Exp Ther; 2011 Mar; 336(3):874-80. PubMed ID: 21156818
[TBL] [Abstract][Full Text] [Related]
22. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
[TBL] [Abstract][Full Text] [Related]
23. Hsp90 inhibition sensitizes DLBCL cells to cisplatin.
Schmidt L; Issa II; Haraldsdóttir H; Hald JL; Schmitz A; Due H; Dybkær K
Cancer Chemother Pharmacol; 2022 Apr; 89(4):431-440. PubMed ID: 35190872
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.
Hostein I; Robertson D; DiStefano F; Workman P; Clarke PA
Cancer Res; 2001 May; 61(10):4003-9. PubMed ID: 11358818
[TBL] [Abstract][Full Text] [Related]
25. Comparison of inhibitory effects of 17-AAG nanoparticles and free 17-AAG on HSP90 gene expression in breast cancer.
Ghalhar MG; Akbarzadeh A; Rahmati M; Mellatyar H; Dariushnejad H; Zarghami N; Barkhordari A
Asian Pac J Cancer Prev; 2014; 15(17):7113-8. PubMed ID: 25227799
[TBL] [Abstract][Full Text] [Related]
26. Targeting acid ceramidase sensitises head and neck cancer to cisplatin.
Roh JL; Park JY; Kim EH; Jang HJ
Eur J Cancer; 2016 Jan; 52():163-72. PubMed ID: 26687835
[TBL] [Abstract][Full Text] [Related]
27. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
Maloney A; Clarke PA; Naaby-Hansen S; Stein R; Koopman JO; Akpan A; Yang A; Zvelebil M; Cramer R; Stimson L; Aherne W; Banerji U; Judson I; Sharp S; Powers M; deBilly E; Salmons J; Walton M; Burlingame A; Waterfield M; Workman P
Cancer Res; 2007 Apr; 67(7):3239-53. PubMed ID: 17409432
[TBL] [Abstract][Full Text] [Related]
28. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Kuruma H; Beraldi E; Fazli L; Zoubeidi A; Gleave ME
Cancer Res; 2011 Sep; 71(17):5838-49. PubMed ID: 21737488
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Ohba S; Hirose Y; Yoshida K; Yazaki T; Kawase T
J Neurosurg; 2010 Jan; 112(1):33-42. PubMed ID: 19408974
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Hsp90 via 17-DMAG induces apoptosis in a p53-dependent manner to prevent medulloblastoma.
Ayrault O; Godeny MD; Dillon C; Zindy F; Fitzgerald P; Roussel MF; Beere HM
Proc Natl Acad Sci U S A; 2009 Oct; 106(40):17037-42. PubMed ID: 19805107
[TBL] [Abstract][Full Text] [Related]
31. Expression of interleukin-6 is downregulated by 17-(allylamino)-17-demethoxygeldanamycin in human prostatic carcinoma cells.
Tsui KH; Feng TH; Hsieh WC; Chang PL; Juang HH
Acta Pharmacol Sin; 2008 Nov; 29(11):1334-41. PubMed ID: 18954528
[TBL] [Abstract][Full Text] [Related]
32. RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems.
Shin D; Kim EH; Lee J; Roh JL
Redox Biol; 2017 Oct; 13():219-227. PubMed ID: 28582730
[TBL] [Abstract][Full Text] [Related]
33. HSP27 expression levels are associated with the sensitivity of hepatocellular carcinoma cells to 17-allylamino-17-demethoxygeldanamycin.
Cui Y; Wu W; Zhou Y; Xie Q; Liu T; Jin J; Liu K
Future Oncol; 2013 Mar; 9(3):411-8. PubMed ID: 23469976
[TBL] [Abstract][Full Text] [Related]
34. A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.
Tse AN; Klimstra DS; Gonen M; Shah M; Sheikh T; Sikorski R; Carvajal R; Mui J; Tipian C; O'Reilly E; Chung K; Maki R; Lefkowitz R; Brown K; Manova-Todorova K; Wu N; Egorin MJ; Kelsen D; Schwartz GK
Clin Cancer Res; 2008 Oct; 14(20):6704-11. PubMed ID: 18927314
[TBL] [Abstract][Full Text] [Related]
35. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells.
Li D; Marchenko ND; Schulz R; Fischer V; Velasco-Hernandez T; Talos F; Moll UM
Mol Cancer Res; 2011 May; 9(5):577-88. PubMed ID: 21478269
[TBL] [Abstract][Full Text] [Related]
36. P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines.
Shintani S; Zhang T; Aslam A; Sebastian K; Yoshimura T; Hamakawa H
Int J Oncol; 2006 Nov; 29(5):1111-7. PubMed ID: 17016641
[TBL] [Abstract][Full Text] [Related]
37. The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development.
Joly AL; Deepti A; Seignez A; Goloudina A; Hebrard S; Schmitt E; Richaud S; Fourmaux E; Hammann A; Collura A; Svrcek M; Jego G; Robinet E; Solary E; Demidov O; Kohli E; Garrido C
Oncogene; 2016 Jun; 35(22):2842-51. PubMed ID: 26364610
[TBL] [Abstract][Full Text] [Related]
38. Combination of HSP90 and autophagy inhibitors promotes hepatocellular carcinoma apoptosis following incomplete thermal ablation.
Chen F; Xie H; Bao H; Violetta L; Zheng S
Mol Med Rep; 2020 Jul; 22(1):337-343. PubMed ID: 32319654
[TBL] [Abstract][Full Text] [Related]
39. A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition.
Kim EH; Jang H; Roh JL
Mol Cancer Ther; 2016 Nov; 15(11):2620-2629. PubMed ID: 27550943
[TBL] [Abstract][Full Text] [Related]
40. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.
Ramanathan RK; Trump DL; Eiseman JL; Belani CP; Agarwala SS; Zuhowski EG; Lan J; Potter DM; Ivy SP; Ramalingam S; Brufsky AM; Wong MK; Tutchko S; Egorin MJ
Clin Cancer Res; 2005 May; 11(9):3385-91. PubMed ID: 15867239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
